Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00475202|
Recruitment Status : Unknown
Verified May 2007 by Assaf-Harofeh Medical Center.
Recruitment status was: Recruiting
First Posted : May 21, 2007
Last Update Posted : May 21, 2007
Diabetic foot ulcers are a major cause of morbidity and mortality, accounting for approximately two-thirds of all non-traumatic amputations performed in the United States. The cost of foot ulcers in diabetic patients averages almost $28,000 for the two years after diagnosis of the ulcer. Hyperbaric oxygen (HBO) serves as primary or adjunctive therapy for a diverse range of medical conditions. HBO also has been used as an adjunct to antibiotics, debridement, and revascularization in the therapy of chronic, nonhealing wounds associated with diabetes or non-diabetic vascular insufficiency.
The aim of the study is to assess whether hyperoxia induced angiogenesis in diabetic patients with foot ulcers.
|Condition or disease|
|Diabetic Foot Ulcers Hyperbaric Therapy Angiogenesis|
|Study Type :||Observational|
|Observational Model:||Defined Population|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00475202
|Contact: Albert Rabinovitz, MDfirstname.lastname@example.org|
|Institute of Hyperbaric Medicine and Wound Care Clinic at Assaf Harofeh Medical Center||Recruiting|
|Zerifin, Israel, 70300|
|Contact: Albert Rabinovitz, MD +972-546-39503 email@example.com|
|Principal Investigator:||Albert Rabinovitz, MD||Assaf-Harofeh Medical Center|
|Study Chair:||Efrati Shai, MD||Assaf-Harofeh Medical Center|